Psychedelic-Assisted Therapies

Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Psychedelics Reform Update: Missouri's $10M Budget, Maine's & Maryland's Study Groups, Oregon's Re-Crim And More
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More

Psychedelic-Assisted Therapies Recent News

Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Psychedelics Update: Task Forces In Three States, Decrim No-Go, Arizona Psilocybin Centers, Utah And More
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
Psychedelics Reform Update: Connecticut's Decriminalization, Vermont Hearings, Arizona's Psilocybin Services & More
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
LSD Microdosing For Depression? This Clinical Study Reveals Promising Results
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Medford Massachusets Move To Decriminalize Psychedelics Has Statewide Reform Implications
FDA Hosts Public Psychedelics Discussion, Discloses Major Growth On Number Of New Psychiatric Drugs Filings Post-2000
FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development.
'Rainforests Are Nature's Medicine Cabinets': Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challenges
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.